| Filed On | Filing |
|---|---|
| 10 Nov 2026 |
Form 4: Cozadd Bruce C, Director
Received 86,500 shares by exercise or conversion ($11.8M) · Sold 68,808 shares ($16.2M) |
| 06 Nov 2026 |
Form 4: Carr Patricia, SVP, Chief Accounting Officer
Received 1,250 shares by exercise or conversion ($175K) · Sold 1,413 shares ($327K) |
| 06 Nov 2026 | 144 |
| 05 Nov 2026 |
Form 4: Gala Renee D, Director
Sold 1,000 shares ($225K) |
| 05 Nov 2026 | SCHEDULE 13G/A |
| 04 Nov 2026 |
Form 4: Cozadd Bruce C, Director
Sold 6,000 shares ($1.3M) |
| 04 Nov 2026 | 144 |
| 03 Nov 2026 | 144 |
| 02 Nov 2026 | 144 |
| 02 Nov 2026 | 10-Q |
| 02 Nov 2026 |
8-K: Results of Operations and Financial Condition
– Broad commercial execution drives record quarterly revenues of $1.2 billion (+10% YoY) – |
| 26 Oct 2026 |
8-K: Results of Operations and Financial Condition
Estimated Q3 Financial Impacts Related to the Actio Biosciences, Inc. Acquisition |
| 09 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On October 6, 2026, Samantha Pearce, Executive Vice President, Chief Commercial Officer of Jazz Pharmaceuticals plc (the “Company”), notified the Company of her intent to retire from her role as Chief Commercial Officer upon the earlier ... |
| 08 Oct 2026 | 144 |
| 07 Oct 2026 |
Form 4: Gala Renee D, Director
Sold 2,000 shares ($473K) |
| 06 Oct 2026 | 144 |
| 05 Oct 2026 |
Form 4: Cozadd Bruce C, Director
Sold 6,000 shares ($1.38M) |
| 01 Oct 2026 | 144 |
| 23 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
This AMENDMENT No. 4, dated as of September 23, 2026 (this “Amendment”), to the Credit Agreement, dated as of May 5, 2021 (as amended by that certain LIBOR Successor Rate Conforming Changes Amendment, dated as of June 7, 2023, that certa... |
| 15 Sep 2026 |
8-K: Regulation FD Disclosure
Acquisition adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1-related epilepsy |
Loading...